Craig Strathdee, PhD, CSO, is the Chief Scientific Officer and a cofounder of Ovie Therapeutics.  Prior to joining Ovie, Dr. Strathdee was a Senior Director at Oncorus Inc., a publicly-traded, immuno-oncology clinical-stage company, where he was responsible for directing the company’s s next-generation immunotherapy platform using herpes simplex-based oncolytic viruses.

​

Prior to working at Oncorus, Dr. Strathdee held successive senior positions at The Broad Institute, Amgen and Immunex, where he led and managed multi-disciplinary teams across various stages of drug development using small molecule- and biologics-based modalities. He has extensive expertise in using genetic perturbation technologies such as RNAi, CRISPR, and ORF expression for drug discovery and phenotypic screens. Dr. Strathdee is widely published and holds multiple patents in the fields of cancer drug discovery and human genetics.

​

Dr. Strathdee received his PhD in molecular biology from the University of Guelph, followed by training as a post-doctoral fellow in human genetics at the Hospital for Sick Children in Toronto.